JP2018522843A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522843A5
JP2018522843A5 JP2017564450A JP2017564450A JP2018522843A5 JP 2018522843 A5 JP2018522843 A5 JP 2018522843A5 JP 2017564450 A JP2017564450 A JP 2017564450A JP 2017564450 A JP2017564450 A JP 2017564450A JP 2018522843 A5 JP2018522843 A5 JP 2018522843A5
Authority
JP
Japan
Prior art keywords
carboxy
ethoxy
amino
butanoyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564450A
Other languages
English (en)
Japanese (ja)
Other versions
JP6731958B2 (ja
JP2018522843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063429 external-priority patent/WO2016198682A1/en
Publication of JP2018522843A publication Critical patent/JP2018522843A/ja
Publication of JP2018522843A5 publication Critical patent/JP2018522843A5/ja
Application granted granted Critical
Publication of JP6731958B2 publication Critical patent/JP6731958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564450A 2015-06-12 2016-06-13 選択的pyy化合物及びその使用 Active JP6731958B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171785 2015-06-12
EP15171785.7 2015-06-12
PCT/EP2016/063429 WO2016198682A1 (en) 2015-06-12 2016-06-13 Selective pyy compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2018522843A JP2018522843A (ja) 2018-08-16
JP2018522843A5 true JP2018522843A5 (enExample) 2019-07-11
JP6731958B2 JP6731958B2 (ja) 2020-07-29

Family

ID=53404384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564450A Active JP6731958B2 (ja) 2015-06-12 2016-06-13 選択的pyy化合物及びその使用

Country Status (19)

Country Link
US (1) US10005824B2 (enExample)
EP (1) EP3307768B1 (enExample)
JP (1) JP6731958B2 (enExample)
KR (1) KR102476550B1 (enExample)
CN (1) CN107849110B (enExample)
AR (1) AR104984A1 (enExample)
AU (1) AU2016275735B2 (enExample)
BR (1) BR112017025108A2 (enExample)
CA (1) CA2988500A1 (enExample)
ES (1) ES3019234T3 (enExample)
IL (1) IL255781B (enExample)
MA (1) MA43205A (enExample)
MX (1) MX392572B (enExample)
MY (1) MY187047A (enExample)
RU (1) RU2726777C2 (enExample)
SA (1) SA517390445B1 (enExample)
TW (1) TWI694082B (enExample)
WO (1) WO2016198682A1 (enExample)
ZA (1) ZA201707782B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2651398T3 (pl) 2010-12-16 2018-05-30 Novo Nordisk A/S Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
JP6629198B2 (ja) 2013-11-15 2020-01-15 ノヴォ ノルディスク アー/エス 35位にβ−ホモアルギニン置換を有するHPYY(1−36)
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof
CN109640693A (zh) 2016-06-14 2019-04-16 谱赛科美国股份有限公司 甜菊醇糖苷组合物,生产方法和用途
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114206375A (zh) * 2019-08-07 2022-03-18 诺和诺德股份有限公司 包含pyy化合物和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物
MX2022005661A (es) * 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
KR20230039601A (ko) 2020-04-17 2023-03-21 아이투오 테라퓨틱스, 인코포레이티드 장기간 작용하는 펩티드 티로신 티로신(pyy) 유사체 및 사용 방법
UA130066C2 (uk) 2020-08-07 2025-10-29 Бьорінгер Інгельхайм Інтернаціональ Гмбх Розчинні агоністи рецепторів npy2
KR20230106616A (ko) * 2020-11-09 2023-07-13 엠바크 바이오테크 에이피에스 타키키닌 수용체 매개 장애의 치료에 있어서의 화합물 및 이의 용도
WO2022159395A1 (en) 2021-01-20 2022-07-28 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
IL311411A (en) 2021-09-15 2024-05-01 Viking Therapeutics Inc Preparations and methods for the treatment of metabolic and liver disorders
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
CN118339515A (zh) * 2021-11-30 2024-07-12 日产化学株式会社 具有羟基肉桂酸衍生物的抗蚀剂下层膜形成用组合物
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0692971A4 (en) 1993-03-29 1997-11-12 Univ Cincinnati PEPTID YY ANALOGS AND USES THEREFOR
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
MY133223A (en) 1998-06-08 2007-10-31 Schering Corp Neuropeptide y5 receptor antagonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU2002230843B8 (en) * 2000-12-14 2007-05-17 Amylin Pharmaceuticals, Llc Peptide YY and peptide YY agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
PL205971B1 (pl) 2001-09-24 2010-06-30 Imp Innovations Ltd Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 glp-1 유도체
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN101380476A (zh) 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
CA2550050A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 analogues linked to albumin-like agents
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
PL2060266T3 (pl) 2004-03-17 2012-01-31 7Tm Pharma As Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych
CN100425282C (zh) 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
AU2005224027B2 (en) 2004-03-17 2011-05-26 7Tm Pharma A/S Y2/Y4 selective receptor agonists for therapeutic interventions
EA011860B1 (ru) 2004-03-17 2009-06-30 7ТиЭм ФАРМА А/С Селективные агонисты рецептора y2 для терапевтического воздействия
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
ATE424848T1 (de) 2004-08-12 2009-03-15 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20080033392A (ko) 2005-07-11 2008-04-16 나스텍 파마수티컬 컴퍼니 인코포레이티드 펩타이드 yy의 향상된 점막 전달을 위한 제형들
CA2616583A1 (en) 2005-07-18 2007-01-25 Novo-Nordisk A/S Peptides for use in the treatment of obesity
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
EA200800875A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y2 рецептору, для терапевтического воздействия
EA200800874A1 (ru) 2005-09-21 2008-08-29 7ТиЭм ФАРМА А/С Рецепторные агонисты, селективные к y4 рецептору, для терапевтического воздействия
WO2007065808A2 (en) 2005-12-07 2007-06-14 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor-agonists
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
RU2456018C2 (ru) 2006-07-11 2012-07-20 КьюПиЭс, ЭлЭлСи Фармацевтические композиции для доставки пептидов с замедленным высвобождением
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
WO2008087190A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
CN101970475A (zh) 2007-07-09 2011-02-09 帝国改革有限公司 人类胰多肽(hpp)类似物及其对摄食行为的作用
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
AU2008297885A1 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of GLP-1 as a therapeutic agent
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
WO2009138511A1 (en) * 2008-05-16 2009-11-19 Novo Nordisk A/S Long-acting y2 and/or y4 receptor agonists
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
CN102202681A (zh) 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
WO2011058165A1 (en) * 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2560675A1 (en) 2010-04-20 2013-02-27 Novo Nordisk A/S Long-acting gastrin derivatives
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
SG11201508469YA (en) 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
JP6629198B2 (ja) * 2013-11-15 2020-01-15 ノヴォ ノルディスク アー/エス 35位にβ−ホモアルギニン置換を有するHPYY(1−36)
US10246497B2 (en) * 2013-11-15 2019-04-02 Novo Nordisk A/S Selective PYY compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2017505284A5 (enExample)
RU2017145348A (ru) Селективные соединения пептида yy и их применения
JP6379300B2 (ja) GLP及び免疫グロブリンハイブリッドFc融合ポリペプチド及びその用途
Cho et al. K-cells and glucose-dependent insulinotropic polypeptide in health and disease
JP7761557B2 (ja) グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
JP5669395B2 (ja) 新規化合物および摂食行動に対するその効果
IL317065A (en) Chimeric inducible cytokine receptors
JP2017537612A5 (enExample)
ES2976562T3 (es) Derivado del glucagón
JP2023071869A (ja) グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト
JP2015513544A5 (enExample)
JP2014500880A5 (enExample)
JP2015503539A5 (enExample)
NO20076346L (no) Fremgangsmater for forebygging og behandling av metabolske forstyrrelser og nye pyrazol-o-glykosidderivater
JP2017528419A5 (enExample)
JP2017519024A5 (enExample)
EP2060268A1 (en) Pharmaceutical compositions for pulmonary or nasal delivery of peptides
WO2012033792A3 (en) Treatment of diseases
JP2014129355A5 (enExample)
ES2728405T3 (es) Tratamiento de la infección por virus de hepatitis delta
JP2015517458A5 (enExample)
CN113456820B (zh) 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
EP3257524B1 (en) Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
JP2013511287A5 (enExample)
RU2012126101A (ru) Полипептидный конъюгат